Longevity and Clinical Effectiveness of the Humoral and Cellular Responses to SARS-CoV-2 Vaccination in Hemodialysis Patients
Kidney Int Rep
.
2022 May;7(5):1103-1107.
doi: 10.1016/j.ekir.2022.02.007.
Epub 2022 Feb 22.
Authors
An S De Vriese
1
2
,
Jens Van Praet
1
2
,
Marijke Reynders
3
,
Line Heylen
4
5
,
Liesbeth Viaene
6
,
Rogier Caluwé
7
,
Melanie Schoutteten
4
5
,
Dirk De Bacquer
8
Affiliations
1
Division of Nephrology and Infectious Diseases, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium.
2
Department of Internal Medicine, Ghent University, Ghent, Belgium.
3
Division of Medical Microbiology, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium.
4
Division of Nephrology, Ziekenhuis Oost-Limburg, Genk, Belgium.
5
Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium.
6
Division of Nephrology, AZ Groeninge, Kortrijk, Belgium.
7
Division of Nephrology, OLV Hospital, Aalst, Belgium.
8
Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
PMID:
35224315
PMCID:
PMC8861256
DOI:
10.1016/j.ekir.2022.02.007
No abstract available
Keywords:
COVID-19; SARS-CoV-2; cellular; hemodialysis; immune response; longevity; vaccination.